Countermeasures May Need More Incentives Than Vouchers, Gottlieb Says
With priority review voucher values falling, Congress may want to think about additional incentives for medical countermeasure development, Commissioner Gottlieb tells Senate committee.
You may also be interested in...
Researchers find no significant difference in number of rare pediatric disease treatments starting clinical development before or after incentive was created, but advocates aren't ready to give up on the program yet.
Medicines Development for Global Health is the first nonprofit to earn a priority review voucher for bringing a neglected tropical disease therapy to US approval. Project carried on research from the Wyeth era.
Chimerix CEO tells Congress allocating Project Bioshield a multi-year funding stream would provide more long-term certainty for countermeasure sponsors.